Jeffrey Chou

2.4k total citations · 1 hit paper
60 papers, 1.8k citations indexed

About

Jeffrey Chou is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Jeffrey Chou has authored 60 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 31 papers in Immunology and 12 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Jeffrey Chou's work include CAR-T cell therapy research (33 papers), Cancer Immunotherapy and Biomarkers (25 papers) and Immunotherapy and Immune Responses (21 papers). Jeffrey Chou is often cited by papers focused on CAR-T cell therapy research (33 papers), Cancer Immunotherapy and Biomarkers (25 papers) and Immunotherapy and Immune Responses (21 papers). Jeffrey Chou collaborates with scholars based in United States, Netherlands and Spain. Jeffrey Chou's co-authors include Igor Puzanov, Omid Hamid, Alan Wells, Kevin Gorski, Mohammed Milhem, David R. Minor, Howard L. Kaufman, Lisa Chen, Michael Chastain and Abraham Anderson and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Jeffrey Chou

56 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

2016 435 citations Igor Puzanov, Mohammed Milhem et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeffrey Chou United States	22	1.1k	720	583	410	180	60	1.8k
Sandrine Valsesia‐Wittmann France	19	1.5k 1.4×	788 1.1×	1.4k 2.3×	407 1.0×	112 0.6×	24	2.7k
Angela M. Krackhardt Germany	23	965 0.9×	965 1.3×	769 1.3×	211 0.5×	60 0.3×	58	1.8k
Craig Okada United States	20	749 0.7×	1.7k 2.3×	760 1.3×	154 0.4×	78 0.4×	49	2.6k
Ignacio Moraga United States	22	957 0.9×	1.3k 1.8×	680 1.2×	116 0.3×	84 0.5×	34	2.2k
Francesco Marangoni United States	22	889 0.8×	1.5k 2.1×	601 1.0×	379 0.9×	243 1.4×	40	2.5k
Chad May United States	22	679 0.6×	420 0.6×	1.4k 2.3×	791 1.9×	125 0.7×	35	2.7k
Nicolas Reymond France	18	902 0.8×	1.3k 1.8×	1.1k 2.0×	152 0.4×	374 2.1×	22	2.9k
Nancy L. Lill United States	16	798 0.7×	375 0.5×	1.3k 2.3×	298 0.7×	217 1.2×	20	1.9k
Ranjani Rajapaksa United States	17	807 0.7×	1.3k 1.8×	605 1.0×	122 0.3×	70 0.4×	23	1.9k
Katie A. Matatall United States	13	672 0.6×	693 1.0×	987 1.7×	114 0.3×	159 0.9×	16	2.2k

Countries citing papers authored by Jeffrey Chou

Since Specialization

Citations

This map shows the geographic impact of Jeffrey Chou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Chou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Chou more than expected).

Fields of papers citing papers by Jeffrey Chou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Chou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Chou. The network helps show where Jeffrey Chou may publish in the future.

Co-authorship network of co-authors of Jeffrey Chou

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Chou. A scholar is included among the top collaborators of Jeffrey Chou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Chou. Jeffrey Chou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kluger, Harriet M., Götz Ulrich Grigoleit, Sajeve Thomas, et al.. (2025). Lifileucel tumor‐infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors. Cancer Communications. 45(10). 1229–1234. 3 indexed citations

Ferris, Robert L., Rom S. Leidner, Christine H. Chung, et al.. (2025). Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Journal for ImmunoTherapy of Cancer. 13(8). e011633–e011633. 1 indexed citations

Gogas, Helen, Andrew J.S. Furness, Gino K. In, et al.. (2025). Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor–naive unresectable or metastatic melanoma: updated results from IOV-COM-202 Cohort 1A. 3. 100624–100624.

Sarnaik, Amod A., John M. Kirkwood, James Larkin, et al.. (2024). Dynamics of circulating cytokines and chemokines during and after tumor-infiltrating lymphocyte cell therapy with lifileucel in advanced melanoma patients.. Journal of Clinical Oncology. 42(16_suppl). 9594–9594. 1 indexed citations

Medina, Theresa, Jason Chesney, Eric D. Whitman, et al.. (2023). 119O Long-term efficacy and patterns of response of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144-01 study. Immuno-Oncology Technology. 20. 100591–100591. 7 indexed citations

Thomas, Sajeve, Jason Chesney, Theresa Medina, et al.. (2023). 1086MO Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): Results from the phase II C-144-01 study. Annals of Oncology. 34. S654–S654. 10 indexed citations

Medina, Theresa, Jason Chesney, Eric D. Whitman, et al.. (2023). 776 Long-term efficacy and safety of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: a 4-year analysis of the C-144–01 study. SHILAP Revista de lepidopterología. A873–A873. 5 indexed citations

Hamid, Omid, Alberto Chiappori, John A. Thompson, et al.. (2022). First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 10(10). e005471–e005471. 37 indexed citations

Gutierrez, Martin, Melissa Johnson, David Sommerhalder, et al.. (2022). 727 Interim phase I clinical data of FT538, an off-the-shelf, multiplexed-engineered, iPSC-derived NK cell therapy, combined with monoclonal antibodies in patients with advanced solid tumors. Regular and Young Investigator Award Abstracts. A760–A760. 1 indexed citations

10.

Hu‐Lieskovan, Siwen, Fadi Braiteh, Juneko E. Grilley‐Olson, et al.. (2021). Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration. Targeted Oncology. 16(6). 773–787. 2 indexed citations

11.

Hu‐Lieskovan, Siwen, Gabriel G. Malouf, Ira Jacobs, et al.. (2021). Addressing Resistance to Immune Checkpoint Inhibitor Therapy: An Urgent Unmet Need. Future Oncology. 17(11). 1401–1439. 17 indexed citations

12.

Al-Khami, Amir A., Sawsan Youssef, Yasmina Abdiche, et al.. (2020). Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody. Molecular Cancer Therapeutics. 19(10). 2105–2116. 11 indexed citations

13.

Hamid, Omid, Willeke Ros, John A. Thompson, et al.. (2017). Safety, pharmacokinetics (PK) and pharmacodynamics (PD) data from a phase I dose-escalation study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600) in combination with utomilumab, a 4-1BB agonistic mAb. Annals of Oncology. 28. v406–v406. 2 indexed citations

14.

Puzanov, Igor, Mohammed Milhem, David R. Minor, et al.. (2016). Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. Journal of Clinical Oncology. 34(22). 2619–2626. 435 indexed citations breakdown →

15.

Kanakry, Christopher G., David G. Coffey, Andrea Towlerton, et al.. (2016). Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide. JCI Insight. 1(5). 97 indexed citations

16.

Klippel, Zandra, Jeffrey Chou, Andrea Towlerton, et al.. (2014). Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC. Gene Therapy. 21(3). 337–342. 30 indexed citations

17.

Warren, Edus H., F. A. Matsen, & Jeffrey Chou. (2013). High-throughput sequencing of B- and T-lymphocyte antigen receptors in hematology. Blood. 122(1). 19–22. 19 indexed citations

18.

Chou, Jeffrey, Matthew Fitzgibbon, Christie Mortales, et al.. (2013). Phenotypic and Transcriptional Fidelity of Patient-Derived Colon Cancer Xenografts in Immune-Deficient Mice. PLoS ONE. 8(11). e79874–e79874. 30 indexed citations

19.

Tykodi, Scott S., Nobuharu Fujii, Nathalie Vigneron, et al.. (2008). C19orf48 Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients. Clinical Cancer Research. 14(16). 5260–5269. 43 indexed citations

20.

Odom‐Maryon, Tamara, et al.. (1999). Intrapatient consistency of imaging biodistributions and their application to predicting therapeutic doses in a phase I clinical study of ‐based radioimmunotherapy. Medical Physics. 26(5). 799–809. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact